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Abstract
Background:  Juvenile systemic sclerosis (JSS) is a multisystem connective tissue disease
characterized by skin fibrosis and internal organ involvement. It has a low prevalence, even in a
tertiary facility setting. The purpose of the present study is to describe and analyze the clinical and
laboratory characteristics of a group of children with JSS followed in a single center.
Methods: Clinical charts of children with a diagnosis of JSS who were seen at a tertiary referral
center between 1995 and 2005 were reviewed. Clinical features were recorded and analysed.
Results: Twenty-three patients who met preliminary classification criteria for JSS were included.
Age at first symptom attributable to JSS was 6 (1–14) years, The first symptom attributable to JSS
was Raynaud's phenomenon in 14 cases. Proximal sclerosis (23 patients, 100%), sclerodactyly (21,
91%), Raynaud's phenomenon (19, 83%), and periungual capillaropathy (17, 74%) were the most
consistent clinical findings during follow-up. Respiratory involvement occurred in two thirds of our
patients, and it manifested as dyspnea as well as abnormal imaging and/or pulmonary function tests;
pulmonary hypertension was an infrequent finding. Dysphagia was the commonest gastrointestinal
symptom (9 patients, 39%). The most frequent musculoskeletal symptom was arthralgia (14
children, 6%); symmetrical arthritis was found in 8 (35%) patients. Periungual capillary abnormalities
were evident during physical examination in 17 children; capillaroscopy revealed abnormalities in
all 19 examined patients. ANA were present in 17 (74%) children: homogeneous pattern was the
most frequent (8 patients), nucleolar (5) and speckled (4) were less common.
Conclusion: Raynaud's phenomenon heralds the beginning of the disease. Capilaroscopy is a
major adjuvant in the diagnosis, since autoantibody determination may not offer sensitive and
specific markers. Skin and vascular manifestations are the most common clinical features, while
internal organ involvement is more rare. Cardiopulmonary disease is the most frequent visceral
involvement, leading to significant morbidity.
Background
Juvenile systemic sclerosis (JSS) is a multisystem connec-
tive tissue disease characterized by widespread skin fibro-
sis and internal organ involvement [1]. Recently, a new set
of criteria was developed by an international consensus
conference to allow the classification of children with JSS
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on the basis of clinical and laboratory parameters (Table
1). These preliminary criteria represent a major advance,
since the classification criteria for adult Systemic Sclerosis
of the American College of Rheumatology [2], which have
been applied to children for decades, have not been vali-
dated in pediatric patients.
JSS is rare condition that runs a chronic course. Single
center-based reported series are small, revealing its low
prevalence [3-7]. This fact has made the setting of large
epidemiological and clinical studies difficult to achieve.
The purpose of the present study is to describe and ana-
lyze the clinical and laboratory characteristics of a group
of children with JSS followed in a single center.
Materials and methods
The clinical charts of children with a diagnosis of JSS who
were seen at Hospital de Pediatría "Prof. Dr. Juan P. Gar-
rahan" (a tertiary referral center) between 1995 and 2005
were reviewed. Diagnosis was originally made on clinical
grounds, on the basis of a combination of diffuse sclero-
dermatous skin changes and internal organ involvement,
vascular abnormalities (including Raynaud's phenome-
non) or presence of the following autoantibodies: antinu-
clear (ANA), anti-Scl-70 and anticentromere (ACA).
Moreover, for the purpose of the present study, the new
preliminary classification criteria for JSS [8] were applied
to the patients. All patients who showed signs of another
connective tissue disorder (such as Gottron's papules,
heliotrope or malar rash) or met Kasukawa criteria for
Mixed Connective Tissue Disease (MCTD) were excluded
from this study.
The following demographic and clinical features occur-
ring during the course of the disease were recorded: sex,
age at first symptom related to JSS, age at diagnosis, pres-
ence of cutaneous (edema, sclerosis, sclerodactily, calci-
nosis, digital pitting, telangiectasias, skin thickening as
measured by the Modified Rodnan Skin Score (MRS) [9]),
cardiovascular (Raynaud's phenomenon, nailfold capil-
lary changes, presence of pericarditis, hypertension, car-
diac failure, arrhythmia, abnormalities of EKG,
pulmonary hypertension as detected by Doppler echocar-
diography), respiratory (coughing, pleuritis, clinical and
imaging signs of fibrosis, abnormalities in forced vital
capacity and pulmonary diffusion capacity for carbon
monoxide (DLCO), gastrointestinal (dysphagia, diarrhea,
constipation, gastroesophageal reflux as evidenced by
contrasted radiography or pH monitoring), musculoskel-
etal (arthritis, muscle involvement as defined by the pres-
ence of muscle weakness or elevation of muscle enzymes,
tendon friction rubs, acrosteolysis), renal (proteinuria),
and nonspecific (weight loss, growth retardation, eye dry-
ness, seizures, peripheral neuropathy) symptoms. Pres-
ence of autoantibodies was also recorded: ANA
(performed by indirect immunofluorescence (or IFI) on
Hep II cells), anti Ro, anti La, anti RNP, anti Sm, anti Scl-
70 (performed by immunoprecipitation), and ACA (IFI).
Therapeutic approaches (use of corticosteroids, immuno-
suppressors and vasodilators) were also reviewed.
Results
Demographic and general features
Twenty-three patients were included. They all met provi-
sional classification criteria for JSS: 19 patients met 3 or
more minor criteria, 15 met 4 or more criteria, 12 met 5
or more criteria, and 5 children met 6 criteria. Median
time of follow-up was 5 (1–11) years after their initial
visit. Age at first symptom attributable to JSS was 6 (1–14)
years, and duration of disease at first visit to our center
was 1 (0.5 – 7) years. There was a marked predominance
of girls (21) over boys (2). At the time of this report, only
one patient of this cohort had died.
The first symptom attributable to JSS was Raynaud's phe-
nomenon in 14 cases, skin induration in 7, and edema in
2 patients. Weight loss (weight below the third percentile)
was observed in 15 children, and growth failure (height
below the third percentile) was recorded in 3 patients. The
most frequent clinical features are listed in Table 2.
No clinical finding could be associated to sex, age of onset
or duration of the disease.
Skin involvement
All patients had skin induration proximal to the metacar-
pophalangeal and metatarsophalangeal joints (Figures 1
and 2); 21 (91%) children exhibited sclerodactyly; 11
(48%) patients showed evidence of calcinosis, which was
located in fingers in 10 cases (Figures 3 and 4). Pitting in
the finger pulps was present in 15 (65%) children; all of
them had suffered from Raynaud's phenomenon for a var-
iable length of time. Telangiectasias over the face, neck
and trunk were recorded in 4 patients.
Periungual capillary abnormalities were evident during
physical examination in 17 children; moreover, capillar-
oscopy revealed a wide range of abnormalities (Table 3)
in all 19 examined patients: dilated loops and avascular
areas were the most frequent. The classical scleroderma
(or SD) pattern consisting in the simultaneous presence of
megacapillaries and avascular areas [10] was present in 12
children. In those children in whom a thorough capillar-
oscopic follow-up was performed, there was a trend
towards the progressive waning of megacapillaries and
dilated loops and a growing frequency of avascular areas
along the years.
Skin thickening was obvious in the first visit in all chil-
dren: median MRS was initially 22 (4–40) and slowlyPediatric Rheumatology 2007, 5:6 http://www.ped-rheum.com/content/5/1/6
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decreased over the following years (to a median of 16 at
30 months after the first assessment) (Figure 5). MRS did
not correlate with visceral involvement.
Cardiovascular involvement
Raynaud's phenomenon was present in 19 (83%) chil-
dren, and it was the initial symptom in 14 (61%). Two
patients exhibited pericarditis, and in both cases it was
low grade.
Arrhythmia was present in 2 girls: the first patient devel-
oped ventricular extrasystole, and she died due to this
complication 7 years after disease onset, when she was 16
years old. The other girl had asymptomatic partial right
bundle blockage.
Pulmonary hypertension was detected in 2 patients by
means of abnormal echochardiographic findings. One of
these patients also had evidence of pulmonary fibrosis.
Respiratory involvement
Dyspnea was the most frequent respiratory complaint of
children with JSS: it was present in 6 (26%) children. Dry
coughing was less frequent (2 patients). Chest radiogra-
phy evidenced pulmonary fibrosis in 9 children (mani-
fested as bilateral basal interstitial infiltrates). Thoracic
Table 1: Provisional classification criteria for the classification of Juvenile Systemic Sclerosis [8].
Major criterion (Required)
Proximal (to MCP/MTP joints) skin sclerosis/induration of the skin
Minor criteria (At least two required)
Cutaneous Sclerodactyly
Peripheral vascular Raynaud's phenomenon
Nailfold capillary abnormalities
Digital tip ulcers
Gastrointestinal Dysphagia
Gastro-esophageal reflux
Cardiac Arrhythmias
Heart failure
Renal Renal crisis
New onset arterial hypertension
Respiratory Pulmonary fibrosis (HRCT/radiograph)
Decreased DLCO
Pulmonary arterial hypertension
Neurologic Neuropathy
Carpal tunnel syndrome
Musculoskeletal Tendon friction rubs
Arthritis
Myositis
Serologic Antinuclear antibodies
SSc selective autoantibodies
(anticentromere, anti-topoisomerase I (Scl 70), anti-fibrillarin, anti-PM-
Scl, anti-fibrillin or anti-RNA polymerase I or III)
Table 2: Frequency of symptoms during the course Juvenile Systemic Sclerosis
Symptom # patients (%)
Proximal sclerosis 23 (100)
Sclerodactily 21 (91)
Raynaud's phenomenon 19 (83)
Nailfold capillaries abnormalities 17 (74)
Digital pitting 15 (65)
Arthralgia 14 (61)
Edema 12 (52)
Calcinosis 11 (48)
Weight loss 11 (48)
Dysphagia 9( 3 9 )
Arthritis 8( 3 5 )
Muscle weakness 8( 3 5 )
Dyspnea 6( 2 6 )Pediatric Rheumatology 2007, 5:6 http://www.ped-rheum.com/content/5/1/6
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high resolution computed tomography (HRCT) was
abnormal in 6 of 11 tested children, showing indirect
signs of pulmonary fibrosis (reticular and ground glass
opacification).
Pulmonary function tests (PFT) were abnormal in 15
(65%) children: they all exhibited restrictive incapacity
(manifested as a forced vital capacity ≤ 80%) and in 3 of
them DLCO was also decreased (≤ 80% of predicted nor-
mal). Seven of the 15 patients with abnormal PFTs did not
show any abnormalities in pulmonary imaging. Patients
with abnormal imaging tended to perform worse in FVC
(Figures 6 and 7). Sequential PFTs showed that FVC and
DLCO measurements did not show any meaningful
changes over the years under heterogeneous therapeutic
intervention. Evidence of small airway involvement, as
detected by a decreased forced expiratory flow (FEF25%–
75%), was present in 3 patients.
Gastrointestinal involvement
Dysphagia was the commonest gastrointestinal symptom
(9 patients, 39%). In 4 of these patients no abnormalities
could be found in esophageal function. In the remaining
5 children, gastro esophageal reflux was present in 4 and
esophageal dysmotility in 1. Constipation (4 children)
and diarrhea (2 patients) were less frequent.
Musculoskeletal involvement
The most frequent musculoskeletal symptom was arthral-
gia (14 children, 6%); symmetrical arthritis was found in
8 (35%) patients. Joint flexion contractures were com-
mon, especially over the interphalangeal joints of hands.
Tendons "rubs" were recorded in 3 cases, usually over
elbows and knees.
Eight children (35%) exhibited diffuse, symmetrical mus-
cle weakness, but only 2 of them showed elevated serum
muscle enzymes (creatinine kinase and aldolase).
Acro-osteolysis was found in 6 children who had suffered
from a long-standing Raynaud's phenomenon,
Renal involvement
Renal involvement was rare in this series. All patients had
normal serum creatinine levels and urinalyses. However,
2 girls developed long-lasting, significant proteinuria (in
the range of 500 to 5,000 mg/day). They underwent kid-
ney biopsy, which revealed mesangeal proliferation in
both, with no evidence of vascular, tubular or interstitial
involvement. The proteinuria eventually disappeared over
2 to 5 years in both patients.
Scleroderma renal crisis did not occur in any of the
patients.
Other organic involvement
Xerophthalmia was found in 3 patients, who did not com-
plain of xerostomia. One patient developed a transient
episode of seizures. No peripheral neuropathy was
detected.
Twelve (48%) children showed reduced weight for age,
and height was below the 3rd percentile for age in 3 chil-
dren.
Autoantibody profile
ANA were present in 17 (74%) children: homogeneous
pattern was the most frequent (8 patients), while nucleo-
lar (5) and speckled (4) were also found. ACA was only
observed in 1 patient, who did not show any distinctive
clinical manifestations. Anti-Scl-70 and anti-Ro antibod-
Face of a 9 year-old girl with systemic sclerosis, 5 years after  the disease onset Figure 1
Face of a 9 year-old girl with systemic sclerosis, 5 
years after the disease onset. Tightening of the skin is 
obvious. The patient is not able to close her lips.Pediatric Rheumatology 2007, 5:6 http://www.ped-rheum.com/content/5/1/6
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ies were found in 2 patients each, while rheumatoid fac-
tor, anti-La and anti-RNP antibodies were revealed in one
patient each. One patient with antinucleolar antibodies
showed concomitant presence of anti-La, and another
positive antinucleolar antibody child tested positive for
anti-Scl 70.
None of these autoantibodies showed any correlation
with clinical features.
Pharmacologic treatment
All patients received an immunomodulator for varying
length of time. Methotrexate (10–15 mg/m2/week, SQ)
was used in 16 patients, D-penicillamine (up to 10 mg/
Kg/day or 250 mg/day) in 12 children, and cyclophospha-
mide (Cyc, 500–1,000 mg/m2/month, for 6 months) in 2
patients who had progressive interstitial lung involve-
ment. Systemic corticosteroids were used in 11 children,
in all cases during the first year of the disease or in combi-
nation with Cyc. Vasodilators (nifedipine) were pre-
scribed in 19 patients.
Discussion
JSS is a rare disease. Its diagnosis may be difficult to make
in its early stages, when edema and Raynaud's phenome-
non predominate and skin induration may not be con-
spicuous. Early JSS might therefore resemble other
conditions. This fact, along with the late development of
pitting scars and abnormal radiography evidencing pul-
monary fibrosis (criteria for the classification of adult
patients with systemic sclerosis), and the overlap of JSS
with other rheumatic diseases, lead to the formulation of
classification criteria adapted to children, which will
hopefully allow the appropriate inclusion of patients in
clinical, epidemiological and basic research protocols [8].
The complexity of JSS usually determines the referral of
potential or definite patients with the disease to tertiary
centers, where a multidisciplinary approach is available. It
is in such setting that we have been able to collect the clin-
ical data of a small series of patients with JSS, which is cer-
tainly more numerous than most published series so far.
In general, the frequency of clinical characteristics in our
patients is similar to the one reported in the Padua data-
base [11], of which most of our patients are constituents.
In the present report, we deliberately excluded patients
with overlap syndromes to obtain a more homogeneous
group than the Padua cohort (which included patients
with overlap syndrome and MCTD).
Most patients in our series were girls, and their debut
occurred at a young age. Other series have also showed a
female predominance, as well as later disease onset
[3,5,7,12]. Patients with JSS in our series showed a wide
Proximal calcinosis in a patient with juvenile systemic sclero- sis Figure 3
Proximal calcinosis in a patient with juvenile systemic sclero-
sis.
Distal sclerosis in a patient with juvenile systemic sclerosis  with disease duration of two years Figure 2
Distal sclerosis in a patient with juvenile systemic 
sclerosis with disease duration of two years. Skin is 
shiny and shows a light reddish discoloration over knuckles.Pediatric Rheumatology 2007, 5:6 http://www.ped-rheum.com/content/5/1/6
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range of clinical manifestations. Proximal sclerosis –
which is a sine qua non condition for the diagnosis-scle-
rodactyly, Raynaud's phenomenon, telangiectasia, and
presence of antinuclear antibodies were the most consist-
ent findings. Visceral involvement was less frequent, and
this fact might be related to the short duration of the dis-
ease in our group (median 6 years). However, at this
moment no relationship between the development of
internal organ involvement and duration of disease could
be found.
Skin features in JSS are very similar to the ones observed
in adult patients with systemic scleroderma. Raynaud's
phenomenon usually precludes other findings, among
which are the nailfold capillary changes. These show a
wide spectrum of images, but the SD pattern is prevalent.
Cutolo et al. have shown that changes in capillaroscopy
reflect the different stages of the disease in patients with
adult systemic sclerosis [13].
Skin induration slowly improved along the years, when
pharmacological and physical therapeutic measures were
used. Initially, it was moderate to high in most patients.
Median MRS was 22, slightly higher than the one found
by Scalapino et al. in their pediatric patients at their first
visit (19.4) [12]. Patients with JSS usually develop a pro-
gressive atrophy of the skin, which may be associated with
its thinning and a consequent lower MRS [1,14]. How-
ever, a recent study suggested that the use of the MRS
needs to be validated in children, who show an increased
score even in health, according to body mass index and
Tanner stage [15]. For this reason, a MRS ≥ 14 should be
considered a definite marker of skin thickening. As
opposed to patients with the adult form of systemic scle-
rosis, no classification of patients based on the extent of
skin induration could be made in our group, since all
patients developed widespread, diffuse skin sclerosis, irre-
spective of their autoantibody profile.
Pulmonary disease is the most frequent of visceral
involvement, usually related to pulmonary fibrosis. Respi-
ratory involvement occurred in two thirds of our patients,
and it manifested as dyspnea, abnormalities in imaging,
and in PFTs. As it has been previously reported [3], radio-
graphic changes correlated poorly with pulmonary func-
tion: about only half of our patients with abnormal FVC
or DLCO showed abnormal imaging studies. Restrictive
disease was the most common of spirometric patterns,
while obstructive pattern with small airway involvement
was found in 3 patients in our cohort. Similar findings
have been previously reported by other investigators [6].
Pulmonary disease was not severe in most cases, but pro-
gressive fibrosis led to persistent restrictive incapacity –
with significant impact on the patients' functional capac-
Table 3: Main capillaroscopic findings in a cohort of patients with Juvenile Systemic Sclerosis.
Nailfold capillary abnormalities # patients
Dilated loops 17
Avascular areas 16
Irregular loops 15
Hemorrhages 13
Megacapillaries 12
Dropout 12
Tortuousity 12
Arborization 11
Distal calcinosis in a patient with juvenile systemic sclerosis Figure 4
Distal calcinosis in a patient with juvenile systemic sclerosis.Pediatric Rheumatology 2007, 5:6 http://www.ped-rheum.com/content/5/1/6
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Longitudinal skin thickness evaluation by Modified Rodnan Score in patients with Juvenile Systemic Sclerosis Figure 5
Longitudinal skin thickness evaluation by Modified Rodnan Score in patients with Juvenile Systemic Sclerosis. 
Each colour represents a patient.
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Forced vital capacity (FVC) in a cohort of patients with Juvenile Systemic Sclerosis Figure 6
Forced vital capacity (FVC) in a cohort of patients with Juvenile Systemic Sclerosis. Tests were performed every 
six months. Patients with normal pulmonary imaging. Each colour represents a patient
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ity- and abnormal pulmonary imaging in 2 children.
These patients were treated with corticosteroids and IV
cyclophosphamide for six months. After therapy PFTs
seemed to stabilize over the following years. This thera-
peutic approach has proved efficacious in adult patients
with systemic sclerosis. [16] On the other hand, all other
patients did not show significant changes in their PFTs
during follow-up. Garty et al. showed a similar behavior
of PFTs in a followed cohort for 5 years [6].
Cardiovascular symptoms were not common in our
group. In particular, pulmonary hypertension was an
infrequent finding. The small number of patients with
reduced DLCO reflects this fact. DLCO impairment is a
marker of pulmonary vascular involvement, while
decreased FVC usually indicates the presence of interstitial
involvement [17]. Patients were treated with vasodilators,
and at the time of this report pulmonary artery pressure is
considered to be mildly elevated. Cardiac catheterization
has not been performed in our patients
Although arrhythmia is an infrequent finding in children
with JSS, it is a potentially severe complication that may
be life-threatening, as evidenced by one of our patients.
Heart disease has been the cause of death in several previ-
ously reported cases [3,6,18,19].
Esophageal dysfunction is the main cause of gastrointesti-
nal morbidity in children with JSS [1]. It was present in
40% of our patients and it lead to significant discomfort.
Dysphagia, diarrhea, intestinal involvement and anorexia
may contribute to the marked weight loss observed in the
majority of children. Since only radiography and pH
monitoring were the methods used to detect gastro-
esophageal reflux, it may have been missed in some
patients. Esophageal manometry, which was not per-
formed in our patients, is a very sensitive method for
detecting lower esophageal dysfunction [20].
As previously noticed in the report from the Padua data-
base [11], arthralgia, arthritis and joint contractures were
the most frequent musculoskeletal findings in our group.
Myositis (proximal symmetrical muscle weakness accom-
panied by elevation of muscle enzymes) was observed in
2 patients. Similarly to previously reported cases of myosi-
tis in JSS [5,18], these patients exhibited restrictive pattern
in PFTs and dysphagia due to esophageal dysfunction.
However, none of them presented any myocardial
involvement.
As opposed to adult patients with systemic scleroderma,
"specific" autoantibodies are not common in the pediatric
form of the disease [12,21]. Besides ANA – which
Forced vital capacity (FVC) in a cohort of patients with Juvenile Systemic Sclerosis Figure 7
Forced vital capacity (FVC) in a cohort of patients with Juvenile Systemic Sclerosis. Tests were performed every 
six months. Patients with abnormal pulmonary radiography and/or computed tomography. Each colour represents a patient.
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occurred in the majority of patients- only 3 children
showed antitopoisomerase-I (anti-Scl-70) or anticentro-
mere antibodies, frequent markers of the disease in adults.
On the other hand, the nucleolar pattern of the ANA was
observed in 5 of our patients. Other investigators have
reported this particular staining in children with JSS
[5,22].
Pharmacological management of our patients included
the use of immunomodulators. D-penicillamine was pro-
gressively replaced by methotrexate in the routine practice
in our Service. In general, the appreciation of the efficacy
of this overall therapy in our patients was considered to be
satisfactory, in accordance with previous series [19]. One
patient (out of 17 followed for at least 5 years) died. The
resultant 5-year survival for our group is 94%, which coin-
cides with previously reported survival rates [19] and
seems to be better than the survival of patients in previous
decades [4].
Conclusion
JSS is a low-prevalence disease and incidental cases are
very sporadic, even in a tertiary facility setting (2.3 new
cases/year in our center). This is, to the best of our knowl-
edge, the largest single-center based JSS cohort reported so
far. Raynaud's phenomenon heralds the beginning of the
disease. Capillaroscopy is a major adjuvant in the diagno-
sis, since autoantibody determination may not offer sen-
sitive and specific markers. Skin and vascular
manifestations are the most common clinical features,
while internal organ involvement is more rare. However,
cardiopulmonary disease is the most frequent visceral
involvement, leading to significant morbidity, and poten-
tially death. Prospective, multicentric studies with longer
follow-up are needed to assess the natural history of the
disease, survival, and provide the clinical basis for even-
tual clinical trials in the future.
Acknowledgements
We are grateful to Francesco Zulian, MD for critical reading of the manu-
script.
Written consent for publication was obtained from the patients or their 
relatives.
References
1. Zulian F, Cassidy JT: The systemic sclerodermas and related
disorders.  In Textbook of Pediatric Rheumatology 5th edition. Edited
by: Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Philadelphia: Elsevier;
2005:442-471. 
2. The American Rheumatism Association Diagnostic and Therapeutic
Criteria Committee, Subcommittee for Scleroderma Criteria: Pre-
liminary criteria for the classification of systemic sclerosis
(scleroderma).  Arthritis Rheum 1980, 23:581-590.
3. Cassidy JT, Sullivan DB, Dabich L, Petty RE: Scleroderma in chil-
dren.  Arthritis Rheum 1977, 20(suppl):351-354.
4. Kornreich HK, King KK, Bernstein BH, Singsen BH, Hanson V: Scle-
roderma in childhood.  Arthritis Rheum 1977, 20(suppl):343-350.
5. Suarez-Almazor ME, Cattoggio LJ, Maldonado-Cocco JA, Cuttica R,
García-Morteo O: Juvenile Progressive systemic sclerosis: clin-
ical and serologic findings.  Arthritis Rheum 1985, 28:699-702.
6. Garty BZ, Athreya BH, Wilmott R, Scarpa N, Doughty R, Douglas SD:
Pulmonary functions in children with progressive systemic
sclerosis.  Pediatrics 1991, 88:1161-1167.
7. Martinez-Cordero E, Fonseca MC, Aguilar León DE, Padilla A: Juve-
nile systemic sclerosis.  J Rheumatol 1993, 20:405-407.
8. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TA,
Cerinic MM, Martini G, Ravelli A, Russo R, Cuttica R, de Oliveira SK,
Denton CP, Cozzi F, Foeldvari I, Ruperto N: The Pediatric Rheu-
matology European Society/American College of Rheuma-
tology/European League against Rheumatism provisional
classification criteria for juvenile systemic sclerosis.  Arthritis
Rheum 2007, 57:203-212.
9. Clements P, Lachenbruch P, Sibold J, White B, Weiner S, Martin R,
Weinstein A, Weisman M, Mayes M, Collier D, Wigley F, Medsger T
Jr, Steen V, Moreland L, Dixon M, Massa M, Lally E, McCloskey D,
Varga J, Ingenito F, Furst D: Inter and intraobserver variability of
total skin thickness score (modified Rodnan TSS) in systemic
sclerosis.  J Rheumatol 1995, 22:1281-1285.
10. Maricq HR, Spencer-Green G, LeRoy EC: Skin capillary abnormal-
ities as indicators of organ involvement in scleroderma (sys-
temic sclerosis), Raynaud's syndrome and dermatomyositis.
Am J Med 1976, 61:862-870.
11. Martini G, Foeldvari I, Russo R, Eberhard A, Cuttica R, Ravelli A: Sys-
temic scleroderma syndrome (SSS) in children: clinical and
immunological characteristics of 181 patients [abstract].
Arthritis Rheum 2003, 48(suppl):s512.
12. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino
AV Jr, Steen V, Medsger TA Jr: Childhood onset systemic sclero-
sis: classification, clinical and serologic features, and survival
in comparison with adult onset disease.  J Rheumatol 2006,
33:1-10.
13. Cutolo M, Sulli A, Pizzorni C, Accardo S: Nailfold videocapillaros-
copy assessment of microvascular damage in systemic scle-
rosis.  J Rheumatol 2000, 27:2722-2723.
14. Murata M, Sato S, Komura K, Shirasaki F, Hasegawa M, Takehara K:
Clinical characteristics of juvenile systemic sclerosis in Japa-
nese [letter].  J Rheumatol 2005, 32:1850-1852.
15. Foeldvari I, Wierk A: Healthy children have a significantly
increased skin score assessed with the modified Rodnan skin
score.  Rheumatology 2006, 45:76-78.
16. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA: Cyclophos-
phamide is associated with pulmonary function and survival
benefit in patients with scleroderma and alveolitis.  Ann Int
Med 2000, 132:947-954.
17. Mehta S, Little S: Screening for pulmonary hypertension in
scleroderma: how and when to look?  J Rheumatol 2006,
33:204-206.
18. Quartier P, Bonnet D, Fournet J-C, Bodemer C, Acar P, Ouachée-
Chardin M, Le Bidois J, Prieur AM: Severe cardiac involvement in
children with Systemic Sclerosis and myositis.  J Rheumatol
2002, 29:1767-1773.
19. Foeldvari I, Zhavania M, Birdi N, Cuttica RJ, de Oliveira SH, Dent PB,
Elborgh R, Falcini F, Ganser G, Girschik H, Hafner R, Joos R, Kuis W,
Pelkonen P, Prieur AM, Rostropowicz-Denisiewicz K, Russo R, Savol-
ainen A, Siamopoulou-Mayridou A, Zulian F: Favourable outcome
in 135 children with juvenile systemic sclerosis: results of a
multi-national survey.  Rheumatology 2000, 39:556-559.
20. Flick JA, Boyle JT, Tuchman DN, Athreya BH, Doughty RA: Esopha-
geal motor abnormalities in children and adolescents with
scleroderma and mixed connective tissue disease.  Pediatrics
1988, 82:107-111.
21. Vancheeswaran R, Black CM, David J, Hasson N, Harper J, Atherton
D, Trivedi P, Woo P: Childhood-onset scleroderma. Is it differ-
ent from adult-onset disease?  Arthritis Rheum 1996,
39:1041-1049.
22. Bernstein RM, Pereira RS, Holden AJ, Black CM, Howard A, Ansell
BM: Autoantibodies in childhood scleroderma.  Ann Rheum Dis
1985, 44:503-506.